maintain positive view on property market in long-term, specially demand for high-quality residential property and office space. For the plan on residential property business, in 2Q19, the Company had signed
(21.62) (4.64) 16.98 365.95% (21.72) (10.95) 10.77 98.36% Profit Sharing for the Period - The Company’s Equity (21.52) (4.86) 16.66 342.80% (22.24) (11.19) 11.05 98.75% - Non-controlling Interest (0.10
progressed 62.79% (The construction plan was 62.55%). The commercial operation date is scheduled in the second quarter of 2022. Page 3 1.2 Additional Investments in Joint Ventures - On September 25, 2019, EGCO
liabilities 2,235.76 87.54% 2,275.47 87.98% 39.71 1.78% Total shareholders' equity 318.23 12.46% 310.78 12.02% (7.45) (2.34%) Total liabilities and shareholders' equity equity
transaction : The Company has a plan to do the potential growth business especially health and aging society business relating with the main business of the Company, medical device business. Value of
% Core EBITDA/ton ($) 102 113 140 (27%) 128 120 7% Operating Cash Flow5 261 250 241 8% 1,010 872 16% Net Debt to Equity (times) 0.92 0.87 0.61 51% 0.92 0.61 51% 1Consolidated financials are based upon
)% 4.12 3.26 26% Core EBITDA/ton ($) 102 113 140 (27%) 128 120 7% Operating Cash Flow5 261 250 241 8% 1,010 872 16% Net Debt to Equity (times) 0.92 0.87 0.61 51% 0.92 0.61 51% 1Consolidated financials are
107 42% 132 97 36% Operating Cash Flow 240 249 258 (7)% 923 966 (4)% Net Operating Debt to Equity (times) 0.45 0.39 0.84 (46)% 0.45 0.84 (46)% 1Consolidated financials are based upon elimination of
restructuring plan of the Company including the scheduling of shareholders’ meeting of the Company within April 2019 to consider the Company’s capital increase. The Company may initially consider to increase its
capital restructuring plan of the Company including the scheduling of shareholders’ meeting of the Company within April 2019 to consider the Company’s capital increase. The Company may initially consider to